Bloom SR - Search Results

1

PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.

Field BC, Wren AM, Peters V, Baynes KC, Martin NM, Patterson M, Alsaraf S, Amber V, Wynne K, Ghatei MA, Bloom SR. Field BC, et al. Among authors: bloom sr. Diabetes. 2010 Jul;59(7):1635-9. doi: 10.2337/db09-1859. Epub 2010 Mar 31. Diabetes. 2010. PMID: 20357366 Free PMC article. Clinical Trial.

2

Oxyntomodulin suppresses appetite and reduces food intake in humans.

Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA, Bloom SR. Cohen MA, et al. Among authors: bloom sr. J Clin Endocrinol Metab. 2003 Oct;88(10):4696-701. doi: 10.1210/jc.2003-030421. J Clin Endocrinol Metab. 2003. PMID: 14557443 Clinical Trial.

3

Peripheral oxyntomodulin reduces food intake and body weight gain in rats.

Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, Bloom SR. Dakin CL, et al. Among authors: bloom sr. Endocrinology. 2004 Jun;145(6):2687-95. doi: 10.1210/en.2003-1338. Epub 2004 Mar 4. Endocrinology. 2004. PMID: 15001546

4

Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial.

Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, Wren AM, Frost GS, Meeran K, Ghatei MA, Bloom SR. Wynne K, et al. Among authors: bloom sr. Diabetes. 2005 Aug;54(8):2390-5. doi: 10.2337/diabetes.54.8.2390. Diabetes. 2005. PMID: 16046306 Clinical Trial.

5

The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control.

Wynne K, Bloom SR. Wynne K, et al. Among authors: bloom sr. Nat Clin Pract Endocrinol Metab. 2006 Nov;2(11):612-20. doi: 10.1038/ncpendmet0318. Nat Clin Pract Endocrinol Metab. 2006. PMID: 17082808 Review.

6

Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake.

le Roux CW, Borg CM, Murphy KG, Vincent RP, Ghatei MA, Bloom SR. le Roux CW, et al. Among authors: bloom sr. Ann Clin Biochem. 2008 Jan;45(Pt 1):93-5. doi: 10.1258/acb.2007.007068. Ann Clin Biochem. 2008. PMID: 18275682

7

Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs.

Druce MR, Minnion JS, Field BC, Patel SR, Shillito JC, Tilby M, Beale KE, Murphy KG, Ghatei MA, Bloom SR. Druce MR, et al. Among authors: bloom sr. Endocrinology. 2009 Apr;150(4):1712-22. doi: 10.1210/en.2008-0828. Epub 2008 Dec 12. Endocrinology. 2009. PMID: 19074579 Free article.

8

Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment.

Ashby DR, Ford HE, Wynne KJ, Wren AM, Murphy KG, Busbridge M, Brown EA, Taube DH, Ghatei MA, Tam FW, Bloom SR, Choi P. Ashby DR, et al. Among authors: bloom sr. Kidney Int. 2009 Jul;76(2):199-206. doi: 10.1038/ki.2009.114. Epub 2009 Apr 22. Kidney Int. 2009. PMID: 19387475 Free article. Clinical Trial.

9

Prokineticin 2 is a hypothalamic neuropeptide that potently inhibits food intake.

Gardiner JV, Bataveljic A, Patel NA, Bewick GA, Roy D, Campbell D, Greenwood HC, Murphy KG, Hameed S, Jethwa PH, Ebling FJ, Vickers SP, Cheetham S, Ghatei MA, Bloom SR, Dhillo WS. Gardiner JV, et al. Among authors: bloom sr. Diabetes. 2010 Feb;59(2):397-406. doi: 10.2337/db09-1198. Epub 2009 Nov 23. Diabetes. 2010. PMID: 19933997 Free PMC article.

10

Obesity treatment: novel peripheral targets.

Field BC, Chaudhri OB, Bloom SR. Field BC, et al. Among authors: bloom sr. Br J Clin Pharmacol. 2009 Dec;68(6):830-43. doi: 10.1111/j.1365-2125.2009.03522.x. Br J Clin Pharmacol. 2009. PMID: 20002077 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,725 results

Search Page